What is ABECMA? ABECMA (idecabtagene vicleucel) is a prescription medicine for the treatment of multiple myeloma in patients who have received at least three kinds of treatment regimens that have not worked or have stopped working. ABECMA is a medicine made from your own white blood cells; the cells are genetically modified to recognize and attack your multiple myeloma cells.
This website is best viewed using the horizontal display on your tablet device.
This website is best viewed using the vertical display on your mobile device.
In a clinical study of 30.9 months follow-up (median), people treated with ABECMA lived longer without the disease getting worse or passing away, 13.8 months vs 4.4 months with standard treatments.
*Median is the middle number in a group of numbers arranged from lowest to highest.
In an ABECMA clinical study, 386 people were randomly put into 1 of 2 treatment groups:
Everyone in the study had previously received 2 to 4 treatments that had not worked or stopped working, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody. People treated with ABECMA were followed up by their healthcare team at 30.9 months (median‡) to see how well they were responding to treatment.
Click on each tab to see study results.
Overall response:
The percentage of people who responded to treatment.
Complete response or better:
No signs of cancer were found in the body. It does not mean the multiple myeloma has been cured.
People responded to ABECMA for 16.6 months (median).‡
Individual results may vary.
Foot note Standard Treatments:Patients were followed for 30.9 months (median‡).
†Foot note Standard Treatments:People who were given standard treatment got one of the following medication combinations: daratumumab, pomalidomide, dexamethasone (DPd); daratumumab, bortezomib, dexamethasone (DVd); ixazomib, lenalidomide, dexamethasone (IRd); carfilzomib, dexamethasone (Kd); or elotuzumab, pomalidomide, dexamethasone (EPd).
‡Foot note Median:Median is the middle number in a group of numbers arranged from lowest to highest.